Zsa Zsa Weerts

Chapter 7 162 irritable bowel syndrome: a prospective, randomized trial. J Gastroenterol 1997;32:765-768. 23. Lech Y. Olesen K. Hey H, et al. Treatment of irritable bowel syndrome with peppermint oil. A double-blind study with a placebo. Ugeskr Laeger 1988;150:2388-2389. 24. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry - Clinical Evaluation of Drugs for Treatment. 2012. 25. European Medicines Agency (EMA). Guideline on the evaluation of medicinal products for the treatment of irritable bowel syndrome. CHMP/60337. 2013. 26. Chumpitazi B, Kearns G, Shulman R. Review article: the physiological effects and safety of peppermint oil and its efficacy in irritable bowel syndrome and other functional disorders. Aliment Pharmacol Ther 2018;DOI 10.1111/ apt.14519. 27. Schellekens R, Stellaard F, Olsder G, et al. Oral ileocolonic drug delivery by the colopulse-system: a bioavailability study in healthy volunteers. J Control Release 2010;146:334-340. 8. European Medicines Agency (EMA). Public Statement on the use of herbal medicinal products containing pulegone and menthofuran. 2016. 29. Francis C, Morris J, Whorwell P. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 1997;11:395-402. 30. Drossman D, Patrick D, Whitehead W, et al. Further validation of the IBS-QOL: a disease- specific quality-of-life questionnaire. Am J Gastroenterol 2000;95:999. 31. Versteegh M, Vermeulen K, Evers S. Dutch Tariff for the Five-Level Version of EQ-5D. Value Health 2016:19:343-352. 32. Bushnell D, Martin M, Ricci J. Performance of the EQ-5D in patients with irritable bowel syndrome. Value Health 2006;9:90-97. 33. Spitzer R, Kroenke K, Williams J, et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 2006;166:1092-1097. 34. Lowe B, Grafe K, Zipfel S, et al. Detecting panic disorder in medical and psychosomatic outpatients: comparative validation of the Hospital Anxiety and Depression Scale, the Patient Health Questionnaire, a screening question, and physicians' diagnosis. J Psychosom Res 2003;55:515-519. 35. Khanna R, MacDonald J, Levesque B. Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis. J Clin Gastroenterol 2014;48:505-512. 36. Eldridge S, Ashby D, Kerry S. Sample size for cluster randomized trials: effect of coefficient of variation of cluster size and analysis method. Int J Epidemiol 2006;35:1292-1300. 37. Alammar N, Wang L, Saberi B, et al. The impact of peppermint oil on the irritable bowel syndrome: a meta-analysis of the pooled clinical data. BMC Complement Altern Med 2019;19:21. 38. Rao S, Lembo A, Shiff S, et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol 2012;107:1714-1724. 39. Brenner D, Fogel R, Dorn S, et al. Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials. Am J Gastroenterol 2018;113:735-745. 40. Lembo A, Lacy B, Zuckerman M, et al. Eluxadoline for Irritable Bowel Syndrome with Diarrhea. N Engl J Med 2016;374:242-253. 41. Ford A, Talley N, Spiegel B, et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 2008;337:a2313. 42. Corsetti M, Tack J. FDA and EMA end points: which outcome end points should we use in clinical trials in patients with irritable bowel syndrome? Neurogastroenterol Motil 2013;25:453-457. 43. Lacy B, Lembo A, Macdougall J, et al. Responders vs clinical response: a critical analysis of data from linaclotide phase 3 clinical trials in IBS-C. Neurogastroenterol Motil 2014;26:326-333. 44. Otten M, Holierhoek Y, Stellingwerf F, et al. Reduce IBS Project: Multiple Therapy Choices and Shared Decision-Making give IBS Patients Self Management and Better Quality of Life. Gastroenterology 2017;152:S45.